AR114369A1 - Dinucleótidos cíclicos como agentes antineoplásicos - Google Patents
Dinucleótidos cíclicos como agentes antineoplásicosInfo
- Publication number
- AR114369A1 AR114369A1 ARP190100352A ARP190100352A AR114369A1 AR 114369 A1 AR114369 A1 AR 114369A1 AR P190100352 A ARP190100352 A AR P190100352A AR P190100352 A ARP190100352 A AR P190100352A AR 114369 A1 AR114369 A1 AR 114369A1
- Authority
- AR
- Argentina
- Prior art keywords
- nra1ra1
- 2nra1ra1
- nra1s
- nra1c
- halogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H19/213—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862629956P | 2018-02-13 | 2018-02-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR114369A1 true AR114369A1 (es) | 2020-08-26 |
Family
ID=67542132
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190100352A AR114369A1 (es) | 2018-02-13 | 2019-02-13 | Dinucleótidos cíclicos como agentes antineoplásicos |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US10519187B2 (https=) |
| EP (1) | EP3752516B1 (https=) |
| JP (1) | JP7296405B2 (https=) |
| KR (1) | KR102950614B1 (https=) |
| CN (1) | CN111902420B (https=) |
| AR (1) | AR114369A1 (https=) |
| CY (1) | CY1125159T1 (https=) |
| DK (1) | DK3752516T3 (https=) |
| ES (1) | ES2909616T3 (https=) |
| HR (1) | HRP20220520T1 (https=) |
| HU (1) | HUE058662T2 (https=) |
| LT (1) | LT3752516T (https=) |
| PL (1) | PL3752516T3 (https=) |
| PT (1) | PT3752516T (https=) |
| RS (1) | RS63128B1 (https=) |
| SI (1) | SI3752516T1 (https=) |
| SM (1) | SMT202200168T1 (https=) |
| TW (1) | TW202003539A (https=) |
| WO (1) | WO2019160884A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10966999B2 (en) | 2017-12-20 | 2021-04-06 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| CN111511754B (zh) | 2017-12-20 | 2023-09-12 | 捷克共和国有机化学与生物化学研究所 | 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| US11110106B2 (en) | 2018-10-29 | 2021-09-07 | Venenum Biodesign, LLC | Sting agonists for treating bladder cancer and solid tumors |
| AU2019371206A1 (en) | 2018-10-29 | 2021-05-27 | Venenum Biodesign, LLC | Novel sting agonists |
| IL294618A (en) * | 2020-01-16 | 2022-09-01 | Bristol Myers Squibb Co | Reagents and their use for the modular synthesis of c-p bonds |
| WO2021206158A1 (ja) | 2020-04-10 | 2021-10-14 | 小野薬品工業株式会社 | がん治療方法 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| AU2006230099B2 (en) | 2005-03-25 | 2012-04-19 | Gitr, Inc. | GITR binding molecules and uses therefor |
| PL1879573T3 (pl) | 2005-05-10 | 2013-05-31 | Incyte Holdings Corp | Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania |
| CA2634198C (en) | 2005-12-20 | 2014-06-03 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| ES2444574T3 (es) | 2006-09-19 | 2014-02-25 | Incyte Corporation | N-hidroxiamidinoheterociclos como moduladores de la indolamina 2,3-dioxigenasa |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| ES2776406T3 (es) | 2007-07-12 | 2020-07-30 | Gitr Inc | Terapias de combinación que emplean moléculas de enlazamiento a GITR |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| JP5583592B2 (ja) | 2007-11-30 | 2014-09-03 | ニューリンク ジェネティクス コーポレイション | Ｉｄｏ阻害剤 |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| EP2473531A4 (en) | 2009-09-03 | 2013-05-01 | Merck Sharp & Dohme | Anti-gitr antibodies |
| US8722720B2 (en) | 2009-10-28 | 2014-05-13 | Newlink Genetics Corporation | Imidazole derivatives as IDO inhibitors |
| PH12012500881A1 (en) | 2009-12-10 | 2017-07-26 | Hoffmann La Roche | Antibodies binding preferentially human csf1r extracellular domain 4 and their use |
| JP5998060B2 (ja) | 2010-03-04 | 2016-09-28 | マクロジェニクス，インコーポレーテッド | Ｂ７−ｈ３と反応性のある抗体、その免疫学的に活性なフラグメントおよびその使用 |
| CN102918061B (zh) | 2010-03-05 | 2016-06-08 | 霍夫曼-拉罗奇有限公司 | 针对人csf-1r的抗体及其用途 |
| CA2789076C (en) | 2010-03-05 | 2017-11-21 | F. Hoffmann-La Roche Ag | Antibodies against human colony stimulating factor-1 receptor and uses thereof |
| MX378336B (es) | 2010-05-04 | 2025-03-10 | Five Prime Therapeutics Inc | Anticuerpos que se unen a factor estimulante de colonias 1 (csf1r). |
| PT2614082T (pt) | 2010-09-09 | 2018-12-03 | Pfizer | Moléculas de ligação a 4-1bb |
| NO2694640T3 (https=) | 2011-04-15 | 2018-03-17 | ||
| KR101970025B1 (ko) | 2011-04-20 | 2019-04-17 | 메디뮨 엘엘씨 | Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들 |
| BR112014012624A2 (pt) | 2011-12-15 | 2018-10-09 | F Hoffmann-La Roche Ag | anticorpos, composição farmacêutica, ácido nucleico, vetores de expressão, célula hospedeira, método para a produção de um anticorpo recombinante e uso do anticorpo |
| RU2014136332A (ru) | 2012-02-06 | 2016-03-27 | Дженентек, Инк. | Композиции и способы применения ингибиторов csf1r |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| EP2847220A1 (en) | 2012-05-11 | 2015-03-18 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| HK1204557A1 (en) | 2012-05-31 | 2015-11-27 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-l1 |
| AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| CN107759690A (zh) | 2012-08-31 | 2018-03-06 | 戊瑞治疗有限公司 | 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法 |
| JP6742903B2 (ja) | 2013-05-02 | 2020-08-19 | アナプティスバイオ インコーポレイティッド | プログラム死−１（ｐｄ−１）に対する抗体 |
| US9676853B2 (en) | 2013-05-31 | 2017-06-13 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind PD-1 |
| EA034666B1 (ru) | 2013-09-13 | 2020-03-04 | Бейджин Свитзерланд Гмбх | Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела |
| MY184154A (en) | 2013-12-12 | 2021-03-23 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| SG10201900002QA (en) | 2014-01-24 | 2019-02-27 | Dana Farber Cancer Institue Inc | Antibody molecules to pd-1 and uses thereof |
| PE20170198A1 (es) * | 2014-06-04 | 2017-04-08 | Glaxosmithkline Ip Dev Ltd | Dinucleotidos ciclicos como moduladores de sting |
| CN108112254B (zh) | 2015-03-13 | 2022-01-28 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| CR20180101A (es) * | 2015-08-13 | 2018-04-12 | Merck Sharp & Dohme | Compuestos di-nucleóticos cíclicos como agonistas de sting |
| RS67188B1 (sr) | 2016-01-11 | 2025-10-31 | Innate Tumor Immunity Inc | Ciklični dinukleotidi za lečenje stanja povezanih sa aktivnošću sting kao što je kancer |
| US11492367B2 (en) * | 2017-01-27 | 2022-11-08 | Janssen Biotech, Inc. | Cyclic dinucleotides as sting agonists |
| KR102709265B1 (ko) * | 2017-07-28 | 2024-09-23 | 브리스톨-마이어스 스큅 컴퍼니 | 항암제로서의 시클릭 디뉴클레오티드 |
| ES2904317T3 (es) * | 2017-08-31 | 2022-04-04 | Bristol Myers Squibb Co | Dinucleótidos cíclicos como agentes anticancerosos |
| US11667663B2 (en) * | 2017-08-31 | 2023-06-06 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
| JP7195317B2 (ja) | 2017-11-10 | 2022-12-23 | 武田薬品工業株式会社 | Ｓｔｉｎｇ調節剤化合物、ならびに製造及び使用する方法 |
-
2019
- 2019-02-11 US US16/272,172 patent/US10519187B2/en active Active
- 2019-02-13 CN CN201980012869.9A patent/CN111902420B/zh active Active
- 2019-02-13 KR KR1020207026044A patent/KR102950614B1/ko active Active
- 2019-02-13 PL PL19707595T patent/PL3752516T3/pl unknown
- 2019-02-13 LT LTEPPCT/US2019/017740T patent/LT3752516T/lt unknown
- 2019-02-13 AR ARP190100352A patent/AR114369A1/es not_active Application Discontinuation
- 2019-02-13 ES ES19707595T patent/ES2909616T3/es active Active
- 2019-02-13 EP EP19707595.5A patent/EP3752516B1/en active Active
- 2019-02-13 SM SM20220168T patent/SMT202200168T1/it unknown
- 2019-02-13 SI SI201930199T patent/SI3752516T1/sl unknown
- 2019-02-13 JP JP2020564814A patent/JP7296405B2/ja active Active
- 2019-02-13 DK DK19707595.5T patent/DK3752516T3/da active
- 2019-02-13 HU HUE19707595A patent/HUE058662T2/hu unknown
- 2019-02-13 RS RS20220372A patent/RS63128B1/sr unknown
- 2019-02-13 PT PT197075955T patent/PT3752516T/pt unknown
- 2019-02-13 WO PCT/US2019/017740 patent/WO2019160884A1/en not_active Ceased
- 2019-02-13 HR HRP20220520TT patent/HRP20220520T1/hr unknown
- 2019-02-13 TW TW108104810A patent/TW202003539A/zh unknown
- 2019-11-14 US US16/683,667 patent/US11339185B2/en active Active
-
2022
- 2022-05-05 CY CY20221100320T patent/CY1125159T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUE058662T2 (hu) | 2022-09-28 |
| EP3752516B1 (en) | 2022-02-23 |
| PT3752516T (pt) | 2022-03-31 |
| SMT202200168T1 (it) | 2022-05-12 |
| DK3752516T3 (da) | 2022-04-11 |
| US10519187B2 (en) | 2019-12-31 |
| TW202003539A (zh) | 2020-01-16 |
| CY1125159T1 (el) | 2024-12-13 |
| LT3752516T (lt) | 2022-05-10 |
| US11339185B2 (en) | 2022-05-24 |
| JP2021513562A (ja) | 2021-05-27 |
| EP3752516A1 (en) | 2020-12-23 |
| JP7296405B2 (ja) | 2023-06-22 |
| KR102950614B1 (ko) | 2026-04-08 |
| US20190248828A1 (en) | 2019-08-15 |
| PL3752516T3 (pl) | 2022-05-02 |
| HRP20220520T1 (hr) | 2022-05-27 |
| KR20200120683A (ko) | 2020-10-21 |
| CN111902420A (zh) | 2020-11-06 |
| WO2019160884A1 (en) | 2019-08-22 |
| CN111902420B (zh) | 2024-02-02 |
| RS63128B1 (sr) | 2022-05-31 |
| US20200079815A1 (en) | 2020-03-12 |
| SI3752516T1 (sl) | 2022-05-31 |
| ES2909616T3 (es) | 2022-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR114369A1 (es) | Dinucleótidos cíclicos como agentes antineoplásicos | |
| AR112290A1 (es) | Dinucleótidos cíclicos como agentes anticáncer | |
| AR115885A1 (es) | Compuestos derivados de 1h-pirazolo[4,3-d]pirimidina como agonistas del receptor 7 tipo toll (tlr7) y su uso en combinación con un agente de inmunoterapia anticancerígeno | |
| AR119424A1 (es) | Derivados de 3-oxo-4h-quinoxalina y oxo-1h-naftiridina como inhibidores de parp | |
| AR109788A1 (es) | Compuestos de benzo[b]tiofeno como agonistas de sting | |
| AR106301A1 (es) | Composiciones de pirrolpirimidina como inhibidores de quinasas | |
| AR119657A1 (es) | Compuestos de pirimidina y composiciones farmacéuticas para prevenir o tratar cánceres que incluyen los mismos | |
| AR088423A1 (es) | Ligadores p1 ciclicos como inhibidores del factor xia | |
| AR115296A1 (es) | Heterocíclicos inhibidores de mat2a y métodos de uso para el tratamiento del cáncer | |
| AR107714A1 (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
| AR099228A1 (es) | Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos | |
| AR117616A1 (es) | Compuestos anti-vih | |
| AR103232A1 (es) | ANTAGONISTAS DE TGFbR | |
| AR109709A1 (es) | Inhibidores de la fosfatidilinositol 3-quinasa | |
| AR091981A1 (es) | Dihidropiridona p1 como inhibidores del factor xia | |
| AR100702A1 (es) | Compuestos inhibidores de quinasa de unión tank | |
| AR112086A1 (es) | Compuestos heteroaromáticos como inhibidores de vanina | |
| AR110405A1 (es) | Compuestos | |
| AR095311A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante | |
| AR099788A1 (es) | Derivados de nucleósidos sustituidos en 4 como inhibidores de la transcriptasa inversa del vih | |
| AR114421A1 (es) | Piperidinil-3-(ariloxi)-propanamidas y propanoatos | |
| AR117900A1 (es) | Pirazolopiridinas y triazolopiridinas como inhibidores de a2a / a2b | |
| AR090835A1 (es) | Derivados de quinazolindiona | |
| AR105975A1 (es) | Sulfonamidas tricílicas limitadas heterocíclicas como agentes contra el cáncer | |
| AR105929A1 (es) | Derivados de 2-difluorometil-nicotin(tio)carboxanilida sustituidos y su uso como fungicidas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |